CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 89,959	$ 81,467
Short-term marketable securities	83,506	211,474
Receivables from collaborative arrangements	14,065	15,868
Amounts due from TRC, LLC	43,534	53,799
Prepaid clinical and development services	10,245	20,374
Other prepaid and current assets	8,561	10,359
Total current assets	249,870	393,341
Property and equipment, net	13,657	16,422
Operating lease assets	39,690	43,260
Equity in net assets of TRC, LLC	67,537	12,750
Restricted cash	837	833
Other assets	3,228	2,451
Total assets	374,819	469,057
Current liabilities:
Accounts payable	3,098	6,775
Accrued personnel-related expenses	12,796	35,238
Accrued clinical and development expenses	17,010	28,799
Accrued general and administrative expenses	2,898	6,048
Accrued interest payable	3,940	3,974
Current portion of non-recourse notes due 2035, net	16,940	19,334
Operating lease liabilities	503	9,867
Deferred revenue	98	11,523
Other accrued liabilities	1,304	2,013
Total current liabilities	58,587	123,571
Convertible senior notes due 2023, net	228,035	226,963
Non-recourse notes due 2035, net	371,359	372,873
Long-term operating lease liabilities	52,681	47,220
Long-term deferred revenue	310	348
Other long-term liabilities	2,420	1,833
Commitments and contingencies
Shareholders' Deficit
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 74,435 and 64,328 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	1,387,469	1,222,818
Accumulated other comprehensive income		47
Accumulated deficit	(1,726,043)	(1,526,617)
Total shareholders' deficit	(338,573)	(303,751)
Total liabilities and shareholders' deficit	$ 374,819	$ 469,057